Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

SHR-A1811 showed promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer, ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

An exploratory analysis of the KEYNOTE-522 study presented at the 2024 San Antonio Breast Cancer Symposium highlights ...

Abdulraheem Yacoub, MD, discusses option for patients with myelodysplastic syndromes and red blood cell transfusion dependence.

Selinexor with ruxolitinib demonstrated encouraging efficacy with a manageable safety profile in patients with myelofibrosis ...

Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.